New Zealand markets closed

Eupraxia Pharmaceuticals Inc. (EPRX)

NasdaqCM - NasdaqCM Delayed price. Currency in USD
Add to watchlist
2.9000-0.0300 (-1.02%)
At close: 04:00PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close2.9300
Open2.9500
Bid2.7300 x 2000
Ask2.8200 x 100
Day's range2.9000 - 3.0000
52-week range2.4800 - 3.5000
Volume19,070
Avg. volume29,661
Market cap103.306M
Beta (5Y monthly)1.19
PE ratio (TTM)N/A
EPS (TTM)N/A
Earnings date09 Aug 2024 - 13 Aug 2024
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • PR Newswire

    Eupraxia Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Corporate Update

    Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (NASDAQ: EPRX) (TSX: EPRX), a clinical-stage biotechnology company leveraging its proprietary DiffuSphere™ technology to optimize drug delivery for applications with significant unmet need, today announced its financial results for the first quarter of 2024 and provided a corporate update.

  • PR Newswire

    Eupraxia Pharmaceuticals Announces Gastrointestinal Clinical Advisory Board

    Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (TSX: EPRX) (NASDAQ: EPRX), a clinical-stage biotechnology company leveraging its proprietary DiffuSphere™ technology to optimize drug delivery for applications with significant unmet need, today announced the formation of a Clinical Advisory Board for its gastrointestinal ("GI") program. The Clinical Advisory Board is comprised of Dr. Evan Dellon (Chairman), Dr. Stephen Attwood, Dr. Albert Bredenoord, Dr. Donna Griebel, Dr. Ikuo Hirano

  • PR Newswire

    Eupraxia Pharmaceuticals Announces Upcoming Presentations at the Osteoarthritis Research Society International World Congress 2024

    Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (TSX: EPRX) (NASDAQ: EPRX), a clinical-stage biotechnology company leveraging its proprietary Diffusphere™ technology to optimize drug delivery for applications with significant unmet need, today announced that the Company will present two abstracts at the upcoming Osteoarthritis Research Society International ("OARSI") World Congress 2024. The meeting is being held in Vienna, Austria from April 18-21, 2024.